XORTX Therapeutics (XRTX) Depreciation & Amortization (CF) (2023 - 2026)

XORTX Therapeutics (XRTX) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $22385.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $22385.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67810.0 (up 73.55% YoY) and the FY2025 annual result came in at $85730.0, down 0.55% from the prior year.
• Depreciation & Amortization (CF) slipped to $22385.0 in Q1 2026, from $22537.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $22888.0 in Q3 2025 to a low of $13672.2 in Q3 2023.
• A 4-year average of $19623.5 and a median of $19536.5 in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 43.06% — and 2025, when it increased 15.5%.
• Tracing XRTX's Depreciation & Amortization (CF) over 4 years: stood at $13672.2 in 2023, then soared by 42.72% to $19513.0 in 2024, then gained by 15.5% to $22537.0 in 2025, then declined by 0.67% to $22385.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $22385.0 (Q1 2026), $22537.0 (Q4 2025), and $22888.0 (Q3 2025), per Business Quant data.